Synopsis {#S0001}
========

**What is the key question?**

Can we use the 6 gene expression signature (6GS) to predict inflammatory phenotype and exacerbation prone patients with COPD?

**What is the bottom line?**

Measurement of the 6GS can significantly and reproducibly discriminate inflammatory phenotypes of COPD, as well as predicting exacerbation prone patients.

**Why read on?**

We demonstrate that the 6GS, a sputum-based molecular signature, is a useful molecular diagnostic tool in COPD phenotype recognition that could be used to guide inflammation-based management of COPD.

Introduction {#S0002}
============

Chronic obstructive pulmonary disease (COPD) is a major global health problem, responsible for a large and increasing burden of illness and death around the world. In 2010, COPD was the fourth global leading cause of death, with this expected to rise to the third leading cause in 2020.[@CIT0001] Therefore, improvements in the diagnosis and management of COPD and exacerbations of COPD are an urgent priority.[@CIT0002] A full understanding of disease pathogenesis and heterogeneity is crucial to advance COPD management and treatment.[@CIT0003] Increased neutrophils in the airways are a well-known feature of COPD whereby neutrophils correlate with clinical severity, however there is a lack of treatments targeting airway neutrophilia. Corticosteroid responsive eosinophilic inflammation is now recognised to account for 10--40% of stable COPD,[@CIT0004] as well as being present during exacerbations.[@CIT0005]

The development of molecular signatures is likely to revolutionise personalised medicine for airway diseases.[@CIT0006] Our previous sputum transcriptomics studies in asthma lead to the identification of a PCR-based gene expression signature of 6 biomarkers that can discriminate inflammatory phenotypes,[@CIT0007],[@CIT0008] predict corticosteroid responsiveness,[@CIT0007],[@CIT0009] and identify exacerbation prone patients.[@CIT0010] The components of the 6 gene expression signature (6GS) are charcot leydon crystal (*CLC*), carboxypeptidase A3 (*CPA3*), DNASE1-like 3 (*DNASE1L3*), which are elevated with eosinophilic airway inflammation, and interleukin-1β (*IL1B*), tissue non-specific alkaline phosphatase (*ALPL*) and chemokine (C-X-C motif) receptor 2 (*CXCR2*), which are elevated with neutrophilic airway inflammation.[@CIT0007] Development of this qPCR biomarker signature as a tool for phenotype prediction will provide significant advantages over traditional cell counting, being faster, with less sample processing, and the potential for the analysis to be automated. Given that similar inflammatory patterns exist in COPD as in asthma, this study aims to determine the diagnostic ability and reproducibility of the 6GS in predicting inflammatory phenotypes and determine prognostic capacity to predict future risk of COPD exacerbation. We hypothesise that the 6GS is a clinically useful biomarker that significantly and reproducibly predicts both inflammatory phenotypes and exacerbation prone COPD patients.

Methods {#S0003}
=======

Study Population {#S0003-S2001}
----------------

We performed 2 studies: a cross-sectional phenotype prediction study (n=132), that assessed the ability of the 6GS in discriminating inflammatory phenotypes of COPD with a sub-group (n=22) that established short-term reproducibility of the gene expression measures, and a prospective cohort study (n=54), that tested the utility and reliability of the 6GS in predicting inflammatory phenotypes, and investigated prediction of exacerbation prone COPD patients, previously reported.[@CIT0011],[@CIT0012] Participants with stable physician-diagnosed COPD were recruited from the respiratory ambulatory care clinics at John Hunter Hospital, the clinical research databases of the John Hunter Hospital's Department of Respiratory and Sleep Medicine and the Hunter Medical Research Institute, Newcastle, Australia. COPD diagnosis was confirmed by incompletely reversible airflow limitation (forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio of \<0.70).[@CIT0013] Exclusion criteria included current smoking (Phenotype prediction study) and unstable COPD, as determined by an acute exacerbation of COPD, which required treatment with antibiotics or oral corticosteroids within the previous 4 weeks, which was cause to delay study visits until recovery. All participants gave written informed consent. The Hunter New England Local Health District and the University of Newcastle Human Ethics Research Committees approved this study (HNEHREC approval numbers of 10/08/18/5.03 and 12/12/12/3.06) which was conducted in accordance with the Declaration of Helsinki.

Clinical Assessments {#S0003-S2002}
--------------------

Participants attended the research centre whereby information on demographics, smoking status, exacerbation history in the preceding year, medical history, medication use, comorbidities (Charlson Comorbidity Index (CCI)[@CIT0014]) and health-related quality of life (Saint George Respiratory Questionnaire (SGRQ)[@CIT0015]) were collected. A 6-minute walk test was performed and the BODE index (Body mass index BMI), airflow Obstruction, Dyspnoea and Exercise capacity) calculated.[@CIT0016] Pre- and post-bronchodilator spirometry[@CIT0017] and sputum induction[@CIT0018] were performed. Peripheral venous blood was collected and serum high-sensitivity C-reactive protein (hs-CRP) was measured using enzyme-linked immunosorbent assay. A subgroup of participants was assessed approximately 1 month later, whereby a second sputum induction was carried out for assessment of reproducibility. In the prospective cohort study, 3 monthly telephone reviews were conducted over 12 months to assess exacerbations and medication use as previously described.[@CIT0011],[@CIT0012]

Exacerbation Capture {#S0003-S2003}
--------------------

Respiratory hospitalisations, emergency department (ED) visits, unscheduled general practice (GP) visits, and medication use including antibiotics and systemic corticosteroids were recorded at each assessment. An exacerbation of COPD was defined as a COPD-related episode with a) hospitalisation; or b) ED visit; or c) the need for oral corticosteroid (OCS) and/or antibiotics for at least 3 days.[@CIT0019] An exacerbation prone patient was defined as a participant with ≥2 exacerbations over the course of the 12 month follow up period.[@CIT0019]

Sputum Induction and Analysis {#S0003-S2004}
-----------------------------

Sputum induction was performed as previously described[@CIT0018] and is described in more detail in the [[Online Supplement](https://www.dovepress.com/get_supplementary_file.php?f=245519.docx)]{.ul}.

Inflammatory Phenotype Classification {#S0003-S2005}
-------------------------------------

The cut off used to define eosinophilic inflammation was ≥3%[@CIT0020]--[@CIT0022] (Eosinophil positive (E^+ve^)-COPD eosinophils≥3%; Eosinophil negative (E^−ve^)-COPD eosinophils\<3%), and for neutrophilic inflammation was ≥61%[@CIT0018],[@CIT0023] (Neutrophil positive (N^+ve^)-COPD neutrophils≥61%; Neutrophil negative (N^−ve^)-COPD neutrophils\<61%). Eosinophilic (E)-COPD was defined as sputum eosinophils≥3% and neutrophils\<61%. Neutrophilic (N)-COPD was defined as sputum neutrophils≥61% and eosinophils\<3%. Mixed granulocytic (MG)-COPD was defined as sputum neutrophils≥61% and eosinophils≥3%, whereas paucigranulocytic (PG)-COPD had normal levels of sputum eosinophils and neutrophils.

6GS Analysis {#S0003-S2006}
------------

Sputum gene expression of *CLC, CPA3, DNASE1L3, IL1B, ALPL, CXCR2* was performed as previously described,[@CIT0007],[@CIT0008] and is described in more detail in the [[Online Supplement](https://www.dovepress.com/get_supplementary_file.php?f=245519.docx)]{.ul}.

Statistical Analysis {#S0003-S2007}
--------------------

Data were analyzed using Stata 13 (Stata Corporation, College Station, Texas, USA) and were reported as mean (SD) or median (quartile 1, quartile 3) depending on the distribution. Comparisons between two independent groups were performed using Student's *t*-test or Wilcoxon Rank Sum test. Fisher's exact test was used to test categorical data. Comparisons between multiple groups were assessed using one-way ANOVA with Bonferroni correction for parametric data and Kruskal Wallis for non-parametric data as indicated. Associations were assessed using Spearman correlation. Biomarker potential was assessed using multiple logistic regression, receiver operating characteristic curves (ROCs) and area under the curve (AUC), described in more detail in the [[Online Supplement](https://www.dovepress.com/get_supplementary_file.php?f=245519.docx)]{.ul}. Reproducibility of 2 qPCR measures approximately 1 month apart (phenotype prediction study) was assessed using Bland-Altman plots and intra-class correlation (ICC, MedCalc software). Agreement of phenotype prediction reliability between the 2 methods (Sputum cell counts and 6GS, prospective cohort study) was assessed using the κ statistic. Significance was accepted when p\<0.05.

Results {#S0004}
=======

Phenotype Prediction Study: Clinical Characteristics and Inflammatory Phenotypes {#S0004-S2001}
--------------------------------------------------------------------------------

Details of the study participants are provided in [Table 1](#T0001){ref-type="table"}. In the phenotype prediction study, participants (n=132) had a mean (SD) age of 70 (8) years and moderate airflow limitation with a mean (SD) post-bronchodilator FEV~1~%predicted of 55 (16)%. Comparison of the characteristics between inflammatory phenotypes of COPD patients is summarised in [Table 2](#T0002){ref-type="table"}. There were 34 (26%) participants with E-COPD, 42 (32%) with N-COPD, 39 (30%) with PG-COPD and 17 (13%) with MG-COPD ([Table 2](#T0002){ref-type="table"}). All clinical characteristics were similar between phenotypes, except for N-COPD having a lower BMI compared with PG-COPD ([Table 2](#T0002){ref-type="table"}).Table 1Summary Clinical Characteristics of the Phenotype Prediction and Prospective Cohort StudiesCharacteristicsPhenotype Prediction StudyProspective Cohort StudyNumber13254Age (years), mean (SD)70 (8)68 (9)Gender, Male n (%)81 (61)25 (46)BMI (kg/m^2^), median (Q1, Q3)29.1 (25.8, 33.6)28.4 (24.2, 31.8)Smoking, n never \| ex \| current21 \| 111 \| 020 \| 30 \| 4Pack years, median (Q1, Q3)42.0 (13.5, 68.1)7.5 (0.0, 35.7)Post β2 FEV~1~%predicted, mean (SD)55 (16)59 (18)Post β2 FVC %predicted, mean (SD)73 (18)80 (17)Post β2 FEV~1~/FVC, mean (SD)54 (15)54 (11)GOLD grades, n 1 \| 2 \| 3 \| 44 \| 79 \| 39 \| 108 \| 30 \| 11 \| 5GOLD quadrant, n A \| B \| C \| D\*18 \| 12 \| 27 \| 40 (n=97)N/AmMRC, mean (SD)1.9 (1.2) (n=97)N/ABDR, n (%)42 (32)32 (59)ICS use, n (%)119 (90)46 (85)ICS dose, BDP equivalent mcg/day, median (Q1, Q3)800 (400, 1600)1000 (250, 2000)CCI, mean (SD)4.1 (1.4)3.8 (1.3)SGRQ total, mean (SD)50.9 (18.6); n=11640.0 (16.6); n=35BODE, median (Q1, Q3)2 (1, 4); n=823 (2, 5); n=35Exacerbation prone, n (%)N/A21 (39)Sputum total cell count (×10^6^/mL), median (Q1, Q3)4.7 (2.9, 8.2)4.5 (2.7, 10.5)Sputum neutrophil %, median (Q1, Q3)55.8 (36.4, 72.1)59.8 (32.0, 75.3)Sputum eosinophil %, median (Q1, Q3)1.8 (0.8, 4.4)1.8 (0.8, 3.0)Inflammatory Phenotype, n (%) E-COPD34 (25.8)8 (14.8) N-COPD42 (31.8)19 (35.2) PG-COPD39 (29.5)20 (37.0) MG-COPD17 (12.9)7 (13.0)Serum CRP, median (Q1, Q3)4.0 (1.9, 10.0); n=1264.2 (1.6, 7.1); n=53[^1] Table 2Phenotype Prediction Study Clinical Characteristics, Inflammatory Cells and Gene Expression Levels in Inflammatory Phenotypes of COPDCharacteristicsE-COPDN-COPDPG-COPDMG-COPDP valueNumber, n (%)34423917Age (years), mean (SD)68 (9)70 (6)72 (8)69 (9)0.358Gender, Male n (%)24 (69)22 (52)25 (64)10 (59)0.504BMI (kg/m^2^), median (Q1, Q3)30.2 (26.8, 33.8)26.8 (23.5, 31.5)\*31.9 (27.5, 37.8)28.6 (26.0, 29.6)0.003Smoking, n never \| ex7 \| 277 \| 354 \| 353 \| 140.657Pack years, median (Q1, Q3)39.3 (3.6, 62.5)43.1 (7.4, 65.0)56.0 (24.0, 92.0)34.5 (7.5, 45.5)Post β2 FEV~1~%predicted, mean (SD)58 (17)51 (18)60 (14)52 (15)0.061Post β2 FVC %predicted, mean (SD)74 (20)72 (17)77 (16)67 (19)0.306Post β2 FEV~1~/FVC, mean (SD)56 (14)49 (14)57 (15)52 (14)0.073GOLD grades, n 1 \| 2 \| 3 \| 41 \| 21 \| 10 \| 22 \| 21 \| 14 \| 51 \| 31 \| 5 \| 20 \| 6 \| 10 \| 10.036BDR, n (%)8 (24)14 (33)17 (44)3 (18)0.171ICS use, n (%)31 (91)41 (98)34 (87)13 (76)0.069ICS dose, BDP equivalent mcg/day, median (Q1, Q3)500 (320, 1000)800 (500, 2000)800 (400, 1000)500 (200, 2000)0.517CCI, mean (SD)3.9 (1.7)4.0 (1.1)4.5 (1.3)4.0 (1.6)0.324SGRQ total, mean (SD)50.1 (20.3); n=3150.4 (16.6); n=3452.2 (17.3); n=3750.5 (24.1); n=140.968BODE, median (Q1, Q3)2.0 (1.0, 3.0); n=213.5 (2.0, 5.0); n=242.0 (1.0, 3.0); n=292.5 (1.0, 3.0); n=80.167**Inflammatory Cells** Sputum total cell count (×10^6^/mL), median (Q1, Q3)3.9 (2.3, 5.4)6.7 (4.0, 17.1)\*^\^^3.3 (2.1, 6.8)8.0 (5.2, 14.7)\*^\^^\<0.001 Sputum neutrophil %, median (Q1, Q3)37.5 (21.8, 48.5)76.5 (68.0, 86.5)\*^\^^41.0 (30.5, 54.3)72.5 (68.5, 76.0)\*^\^^\<0.001 Sputum eosinophil %, median (Q1, Q3)10.8 (4.3, 25.5)\*^\#^1.3 (0.8, 1.5)1.0 (0.5, 1.8)4.0 (3.5, 5.5)\*^\#^\<0.001 Serum CRP, median (Q1, Q3)2.9 (1.4, 4.7)4.5 (2.0, 10.6)5.0 (1.9, 9.0)8.3 (3.0, 14.6)0.066**Gene Expression Biomarkers** CLC mRNA5.3 (0.9, 23.7)\*^\#^0.8 (0.3, 1.5)0.6 (0.2, 1.8)3.1 (1.3, 8.6)\*^\#^\<0.001 CPA3 mRNA7.8 (2.4, 17.3)\*^\#\~^0.9 (0.4, 1.6)0.7 (0.3, 2.1)1.6 (0.2, 6.4)\<0.001 DNASE1L3 mRNA0.8 (0.4, 1.8)\*^\#^0.4 (0.2, 0.7)0.3 (0.1, 0.5)0.6 (0.2, 1.3)\<0.001 IL1B mRNA128.2 (46.7, 353.6)619.9 (205.9, 2143.6)\*^\^^141.6 (60.0, 615.6)228.5 (114.2, 757.9)\<0.001 ALPL mRNA14.4 (9.0, 37.7)85.6 (37.4, 163.7)\*^\^^22.1 (9.6, 50.8)64.3 (18.3, 153.9)^\^^\<0.001 CXCR2 mRNA53.1 (20.1, 125.9)227.9 (82.5, 429.3)\*^\^^58.3 (26.6, 124.1)134.0 (67.5, 406.1)\*\<0.001[^2]

Phenotype Prediction Study: Gene Expression Levels in Inflammatory Phenotypes of COPD {#S0004-S2002}
-------------------------------------------------------------------------------------

Relative gene expression levels of the 6 genes between inflammatory phenotypes are detailed in [Table 2](#T0002){ref-type="table"} and [Figure 1](#F0001){ref-type="fig"}. *CLC* expression was significantly higher in patients with E-COPD and MG-COPD compared with N-COPD and PG-COPD. *CPA3* expression was higher in E-COPD compared with N-COPD, PG-COPD and MG-COPD. *DNASE1L3* expression was higher in E-COPD compared with N-COPD and PG-COPD. Sputum gene expression of *IL1B, ALPL* and *CXCR2* was all higher in N-COPD compared with E-COPD and PG-COPD. *ALPL* expression was higher in MG-COPD compared with E-COPD and *CXCR2* expression was higher in MG-COPD compared with PG-COPD.Figure 1Relative gene expression levels of (**A**) *CLC*, (**B**) *CPA3*, (**C**) *DNASE1L3*, (**D**) *IL1B*, (**E**) *ALPL* and (**F**) *CXCR2* in induced sputum samples from subjects with eosinophilic (E), neutrophilic (N), paucigranulocytic (PG) or mixed granulocytic (MG) COPD. Gene expression is calculated relative to β-actin (ΔCt), log transformed (2^−ΔCt^) and scaled. Bar graphs show the median and error bars as the upper quartile. \*p\<0.01 versus PG-COPD; ^\#^p\<0.01 versus N-COPD; ^\^^p\<0.01 versus MG-COPD; ^\~^p\<0.01 versus E-COPD.

Phenotype Prediction Study: Diagnostic Performance of the Sputum 6GS for Predicting Inflammatory Phenotypes of COPD {#S0004-S2003}
-------------------------------------------------------------------------------------------------------------------

The diagnostic performance of the 6-gene signature, a composite of gene expression results for *CLC, CPA3, DNASE1L3, IL1B, ALPL* and *CXCR2*, was evaluated for predicting inflammatory phenotypes of COPD ([Table 3](#T0003){ref-type="table"}). Firstly, the expression levels of the 6 genes in combination were able to identify participants with COPD that had eosinophilic inflammation compared to those without eosinophilic inflammation ([Figure 2A](#F0002){ref-type="fig"}, E^+ve^-COPD vs E^−ve^-COPD; AUC= 85.8%; 95% CI=79.3--92.3%; p\<0.0001), as well as those participants with COPD that had neutrophilic inflammation compared with those without neutrophilic inflammation ([Figure 2A](#F0002){ref-type="fig"}, N^+ve^-COPD vs N^−ve^-COPD; AUC= 81.1; 95% CI=73.9--88.2%; p\<0.0001).Table 3Phenotype Prediction Study Diagnostic Value of the 6GS for Inflammatory Phenotype of COPDComparisonLogistic RegressionAUCModel p valueMinimal False NegativesMinimal False PositivesCoefficientConstantPredicted Value Cut PointSensitivitySpecificityPredicted Value Cut PointSensitivitySpecificity**E^+ve^-COPD vs E^−ve^-COPD** CLC−0.65101184.92347985.8%\<0.001\>0.38378.4%77.8%\>0.51062.8%87.7% CPA3−0.2845402 DNASE1L30.1376003 IL1B0.1893354 ALPL0.4968448 CXCR2−0.3129282**N^+ve^-COPD vs N^−ve^-COPD** CLC0.0751675−0.655551381.1%\<0.001\>0.37976.3%67.1%\>0.56964.4%84.9% CPA30.0786377 DNASE1L30.188367 IL1B−0.1270903 ALPL−0.4007184 CXCR2−0.2936456**E-COPD vs PG-COPD** CLC−0.35097376.59068988.2%\<0.001\>0.33888.2%69.2%\>0.64470.6%92.3% CPA3--0.4658524 DNASE1L3-0.1730888 IL1B0.1748387 ALPL0.6939474 CXCR2--0.4177731**E-COPD vs N-COPD** CLC−1.12722513.9066596.4%\<0.001\>0.137100.0%76.2%\>0.80170.6%100.0% CPA3--1.012526 DNASE1L3-0.0475856 IL1B1.055443 ALPL0.1515724 CXCR21.063141**E-COPD vs MG-COPD** CLC0.24146591.79504686.2%0.001\>0.49391.2%76.5%\>0.80370.6%82.4% CPA3--0.4802749 DNASE1L3-0.3059183 IL1B--0.1843764 ALPL1.074539 CXCR2--0.1630323**N-COPD vs PG-COPD** CLC−0.0171903−0.223042883.6%\<0.001\>0.47883.3%64.1%\>0.65164.3%92.3% CPA3--0.3571355 DNASE1L30.6163289 IL1B--0.3724894 ALPL-0.0230858 CXCR2--0.7099436**N-COPD vs MG-COPD** CLC1.086616−3.24141187.4%\<0.001\>0.58590.5%64.7%\>0.77271.4%82.4% CPA3--0.0411016 DNASE1L3-0.3322779 IL1B--0.4616068 ALPL-0.4306967 CXCR20.2421647[^3] Figure 2Receiver operating characteristic (ROC) curves demonstrate that the sputum 6GS biomarker discriminates (**A**) eosinophilic (E^+ve^ vs E^−ve^) and neutrophilic (N^+ve^ vs N^−ve^) airway inflammation in COPD, and inflammatory phenotypes (**B**) E-COPD from N, PG and MG-COPD, and (**C**) N-COPD from PG and MG-COPD.

At an optimal predicted value cut point of 0.458 (sensitivity=70.6%, specificity=84.0% and positive likelihood ratio=4.4), the sputum 6GS correctly predicted E^+ve^-COPD from E^−ve^-COPD in 79 of 100 cases. At an optimal predicted value cut point of 0.549 (sensitivity=66.1%, specificity=83.6% and positive likelihood ratio=4.0), the sputum 6-gene signature correctly identified N^+ve^ -COPD from N^−ve^-COPD in 76 of 100 cases.

Furthermore, when splitting the participants into 4 inflammatory phenotypes, 6GS could discriminate E-COPD from PG-COPD (AUC%=88.2; 95% CI=80.3--96.2; p\<0.001), N-COPD (AUC%=96.4; 95% CI=93.2--99.7; p\<0.001), and MG-COPD (AUC%=86.2; 95% CI=74.4--97.9%; p=0.001) ([Figure 2B](#F0002){ref-type="fig"}). The 6GS also distinguished N-COPD from PG-COPD (AUC%=83.7; 95% CI=75.1--92.2; p\<0.001) and MG-COPD (AUC%=87.4; 95% CI=78.2--96.5; p\<0.001) ([Figure 2C](#F0002){ref-type="fig"}).

The optimal predicted value (output of the multiple logistic regression combining 6 genes) cut points for the 6-gene expression signature to distinguish E-COPD from PG-COPD and MG-COPD were 0.484 (sensitivity=82.4%, specificity=82.1% and positive likelihood ratio=4.6, correctly classified 82%), and 0.493 (sensitivity=91.2%, specificity=76.5% and positive likelihood ratio=3.9, correctly classified 86%), respectively. The optimal predicted value cut points for the 6-gene expression signature to distinguish N-COPD from PG-COPD and MG-COPD were 0.503 (sensitivity=78.6%, specificity=71.8% and positive likelihood ratio=2.8, correctly classified 75%), and 0.603 (sensitivity=88.1%, specificity=70.6% and positive likelihood ratio=3.0, correctly classified 83%), respectively.

Phenotype Prediction Study: Reproducibility of the 6GS {#S0004-S2004}
------------------------------------------------------

Sputum gene expression of the 6 biomarkers was measured in 22 participants (n=9 E-COPD, n=9 N-COPD, n=4 PG-COPD) on 2 occasions, a mean (SD) of 37 (20) days apart. Inflammatory phenotype remained the same between the visits. The bias of measurement was small with equal scatter for all genes ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=245519.docx)]{.ul}). ICC coefficients were excellent for *CLC* (0.78) and *IL1B* (0.76), good for *ALPL* (0.65) and *CXCR2* (0.60), fair for *CPA3* (0.45), and poor for *DNASE1L3* (0.33).

Prospective Cohort Study: Using 6GS for Inflammatory Phenotype Prediction {#S0004-S2005}
-------------------------------------------------------------------------

Clinical characteristics of the participants in the prospective cohort study are detailed in [Table 1](#T0001){ref-type="table"}. There were 8 participants with E-COPD, 19 with N-COPD, 20 with PG-COPD and 7 with MG-COPD. To further validate the 6GS prediction of inflammatory phenotypes, we repeated the ROC analysis in this secondary population, which confirmed the 6GS ability to predict phenotypes with high accuracy ([[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=245519.docx)]{.ul}).

To test the clinical utility of the 6GS to predict phenotype in the prospective cohort study (n=54; [Table 1](#T0001){ref-type="table"}), we used the logistic regression equation (detailed in the [[Supplementary Methods](https://www.dovepress.com/get_supplementary_file.php?f=245519.docx)]{.ul} section) to calculate predicted values based on the level of expression of the 6 biomarkers, with the coefficients and constants ([Table 3](#T0003){ref-type="table"}) for each phenotype comparison in question, and the cut points from the ROC curves as described in the phenotype prediction study ([Figure 3](#F0003){ref-type="fig"}).Figure 3Demonstrates the 2 phenotyping strategies that were tested, with (**A**) taking the approach of detecting eosinophilic inflammation first, and then neutrophilic inflammation, and (**B**) vice versa.

Two strategies (two-step process) for predicting the 4 inflammatory phenotypes were tested ([Figure 3](#F0003){ref-type="fig"}). In strategy 1, we first determined the presence of eosinophilic inflammation (E^+ve^ vs E^−ve^-COPD), and secondly the presence of neutrophilic inflammation (in E^+ve^-COPD, E-COPD vs MG-COPD, and in E^−ve^-COPD, N-COPD vs PG-COPD, [Figure 3](#F0003){ref-type="fig"}). We could successfully predict 53% (8/15) of E^+ve^-COPD, and 87% (34/39) of E^−ve^-COPD. Comparison of sputum cell counts and 6GS methods to detect eosinophilic inflammation showed an overall moderate agreement of 78% (expected agreement 62%) with a κ statistic of 0.42 (p\<0.001). When classified into the 4 inflammatory phenotypes, there was an overall moderate agreement of 67% (expected agreement 31%) with a κ statistic of 0.52 (p\<0.001; [Table 4](#T0004){ref-type="table"}).Table 4Prospective Cohort Study Phenotype Prediction, 6GS vs Sputum Cell Counts, Using Strategy 1Sputum Cell Count6GS Strategy 1E-COPDN-COPDPG-COPDMG-COPDTotalE-COPD50308N-COPD0154019PG-COPD5114020MG-COPD13127Total111922254[^4]

In strategy 2, we first determined the presence of neutrophilic inflammation, and secondly the presence of eosinophilic inflammation (in N^+ve^-COPD, N-COPD vs MG-COPD, and in N^−ve^-COPD, E-COPD vs PG-COPD; [Figure 3](#F0003){ref-type="fig"}). We could successfully predict 81% (21/26) of participants with N^+ve^-COPD, and 82% (23/28) participants with N^−ve^-COPD. Comparison of sputum cell counts and 6GS methods to detect neutrophilic inflammation showed an overall substantial agreement of 81.5% (expected agreement 50%) with a kappa statistic of 0.63 (p\<0.001). When classified into the 4 inflammatory phenotypes, there was an overall moderate agreement of 69% (expected agreement 30%) with a κ statistic of 0.55 (p\<0.001; [Table 5](#T0005){ref-type="table"}).Table 5Prospective Cohort Study Phenotype Prediction, 6GS vs Sputum Cell Counts Using Strategy 2Sputum Cell Count6GS Strategy 2E-COPDN-COPDPG-COPDMG-COPDTotalE-COPD60208N-COPD1171019PG-COPD3412120MG-COPD12227Total112317354[^5]

Between the two 6GS phenotype strategies, there was an overall substantial agreement of 76% (expected agreement 32%) with a κ statistic of 0.65 (p\<0.001). However, predicting neutrophilic inflammation first (strategy 2) was slightly improved at predicting inflammatory phenotype as determined by sputum cell count.

Prospective Cohort Study: 6GS and Predicting Exacerbation Prone Patients {#S0004-S2006}
------------------------------------------------------------------------

To further investigate the clinical utility of the 6GS we investigated whether the gene signature could predict exacerbation prone COPD patients (≥2 exacerbations in 12 months following sputum collection, n=21). The 6GS could predict exacerbation prone patients (AUC=77.2%; 95% CI: 63.6--90.8; p=0.034; [Figure 4](#F0004){ref-type="fig"}, [[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=245519.docx)]{.ul}), better than sputum cell counts (6GS vs sputum neutrophil%: p=0.016; 6GS vs sputum eosinophil%: p=0.050; 6GS vs sputum neutrophil% and eosinophil% combined: p=0.029, [Figure 4](#F0004){ref-type="fig"}, [[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=245519.docx)]{.ul}). The optimal predicted cut point for the 6GS to distinguish COPD exacerbation prone patients was 0.539 (sensitivity=57.1%, specificity=90.9% and positive likelihood ratio=6.3, correctly classified 78%).Figure 4Receiver operating characteristic (ROC) curves demonstrate that the sputum 6GS biomarker significantly discriminates COPD participants who experienced frequent (\>2) exacerbations in the following year, whereas sputum neutrophils and eosinophils did not discriminate frequent exacerbators. \*p=0.016 6GS vs sputum neutrophil% (AUC=52.2%, p=0.783), ^\^^p=0.050 vs sputum eosinophils (AUC=57.3%, p=0.370), ^\~^p=0.029 vs sputum eosinophil% and neutrophil% combined (AUC=55.2%, p=0.939).

We then further investigated whether 6GS can predict the type of exacerbations experienced, including hospital admission (n=8), frequent (≥2) GP visits (n=11), frequent (≥2) OCS courses (n=12), and frequent (≥2) antibiotics courses (n=20). The 6GS was able to significantly discriminate future hospitalisation (AUC=87%; p=0.028) and frequent OCS courses (AUC=81.6%; p=0.0156); however, 6GS did not significantly predict frequent GP visits or frequent antibiotic courses from the rest of the group.

Correlations of Gene Expression Markers with Clinical Outcomes {#S0004-S2007}
--------------------------------------------------------------

Elevated gene expression levels of *IL1B* had a weak but significant association with post-bronchodilator FEV~1~%predicted (r=−0.32; p\<0.0001; [Figure 5A](#F0005){ref-type="fig"}). Elevated expression of *ALPL* also correlated with poor lung function (FEV~1~%predicted r=−0.33; p\<0.001). Gene expression of *IL1B* ([Figure 5B](#F0005){ref-type="fig"}; p\<0.001), *ALPL* (p\<0.001) and *CXCR2* (p=0.017) was significantly higher in participants in GOLD grade 4 especially when compared with those in GOLD grades 1 and 2. Neutrophil related signatures were associated with BODE index (*IL1B*: [Figure 5C](#F0005){ref-type="fig"}; r=0.31; p\<0.001, *ALPL*: r=0.32; p=0.002,). *CLC, CPA3* and *DNASE1L3* did not show any significant correlation with above mentioned clinical outcomes.Figure 5Sputum gene expression of IL1B correlates with (**A**) FEV1% predicted; (**B**) GOLD stage and (**C**) BODE index. \*\*p\<0.001 versus GOLD stage 1 and GOLD stage 2; ^\#^p\<0.05 versus GOLD stage 3.

Discussion {#S0005}
==========

This study, which examined the diagnostic ability of a sputum 6GS in predicting airway inflammatory phenotypes in COPD, had a number of significant findings. We have shown that the 6GS can distinguish between patients with different inflammatory phenotypes of COPD, with a substantial degree of accuracy and reproducibility. We demonstrated the clinical utility of 6GS by investigating 2 prediction strategies which showed significant agreement between cell counts and 6GS for detecting COPD phenotype. 6GS was also able to predict participants who experienced frequent (≥2) exacerbations in the following 12 months. Similar to our previous findings in asthma,[@CIT0007] expression of *CLC, CPA3* and *DNASE1L3* was higher in participants with airway eosinophilia, and expression of *IL1B, ALPL* and *CXCR2* was higher in those with airway neutrophilia. Elevated expression levels of genes associated with neutrophilic inflammation, in particular *IL1B*, were associated with poorer lung function, severity (GOLD stage) and a higher BODE index.

There have been significant advances in molecular phenotyping of asthma and asthma-COPD overlap using transcriptomic profiling of samples obtained from bronchial or nasal airway brushings, induced sputum or blood.[@CIT0007],[@CIT0008],[@CIT0024]--[@CIT0030] We have previously discovered and developed a qPCR-based test measuring the expression levels of 6 genes (*CLC, CPA3, DNASE1L3, IL1B, ALPL* and *CXCR2)* in sputum samples, which can reproducibly differentiate inflammatory phenotypes of asthma, predict both ICS[@CIT0007] and OCS[@CIT0009] responsiveness better than sputum eosinophil count, and predict exacerbation prone patients with poorly controlled asthma.[@CIT0010] We confirmed the regulation of expression of the 6GS biomarkers in COPD was similar to asthma, with *CLC, CPA3* and *DNASE1L3* were highly expressed in eosinophilic inflammation, and higher expression of *IL1B, ALPL* and *CXCR2* characterized neutrophilic inflammation.[@CIT0007] The crystal structures of CLC protein have classically been observed in tissues and secretions from eosinophil-associated diseases.[@CIT0031] CPA3 is known to be expressed largely in mast cells,[@CIT0032] but also basophils[@CIT0033] and is differentially expressed in airway epithelial brushings[@CIT0025] and sputum from patients with asthma.[@CIT0034]

In the present study, we show that the 6GS differentiates E-COPD from other inflammatory phenotypes with high accuracy, similar to our asthma data.[@CIT0007],[@CIT0010] Of note, it was not possible to distinguish E-COPD using clinical criteria. This suggests that a genomic approach may be a more reliable, accurate and sensitive means to characterise phenotypes of COPD. Moreover, akin to our findings in asthma,[@CIT0007],[@CIT0010] the present study also showed that *CLC, CPA3* and *DNASE1L3* were highly expressed in E-COPD. This finding may be indicative that eosinophilic inflammation in both asthma and COPD may share common pathways and mechanisms such as the involvement of mast cells[@CIT0034] and basophils, and/or the levels of these mRNAs are overrepresenting the cells of interest, thus providing predictive value of cellular phenotype in sputum regardless of the disease context. Given the similarities between eosinophilia in asthma and eosinophilic COPD, this is a trait that should be targeted with treatments,[@CIT0035] in which case biomarkers to identify suitable patients will be of great advantage.

This study demonstrated that 6GS could also predict exacerbation prone COPD patients, whereas sputum cell counts could not. This may be driven partly by the expression of IL-1β, which we have previously shown, along with IL-1 pathway activation, can predict future frequent exacerbations.[@CIT0011],[@CIT0012] In addition, Bafadhel et al[@CIT0005] have shown that sputum IL-1β levels are also increased in COPD exacerbations, predicting those exacerbations associated with bacterial infection.

COPD exacerbations are associated with higher healthcare burden, disease progression and increased mortality. Further investigation into biomarkers that are predictive of exacerbation susceptibility are of urgent need, as current strategies based on clinical factors, such as exacerbation history[@CIT0019] are limited, and fail to target underlying biological mechanisms. Early intervention gives an opportunity to optimise treatment and prevent progression of the disease. Pulmonary biomarkers for exacerbations have been investigated (reviewed in[@CIT0036]), and show promise, however, no single marker is adequately validated for clinical use. Recent blood biomarker analysis of the SPIROMICS and COPDGene cohorts has shown limited exacerbation prediction, with poor reproducibility between cohorts, and the markers only marginally improving predictive rates of clinical variables.[@CIT0037]

Evidence in the literature suggests that treatment with either OCS or ICS has little effect in lessening neutrophilic airway inflammation in COPD,[@CIT0038],[@CIT0039] and new treatment approaches including selective phosphodiesterase (PDE) inhibitors and macrolide antibiotics[@CIT0003],[@CIT0040] are thus being tested. As Dasgupta et al[@CIT0041] pointed out the key to the success of clinical trials on novel treatment approaches targeting airway inflammation in COPD and asthma mainly depend on the ability to accurately phenotype patients using methods employing non-invasive inflammometry techniques to provide information as to possible mechanisms, mediators or cytokines involved in the disease pathogenesis. Application of molecular signatures, such as the 6GS, has the ability to revolutionise the field of personalised medicine, providing sensitive biomarkers that represent underlying disease endotypes that can be specifically targeted with treatments.

In the present study, we have also succeeded in showing that the sputum 6-gene signature can distinguish MG-COPD from other inflammatory phenotypes of COPD with an excellent accuracy. MG-COPD participants had higher *CLC, ALPL* and *CXCR2*, but no difference in *CPA3, DNASE1L3* or *IL1B*. Interestingly, the MG-COPD group did not appear to have an elevated *CPA3, DNASE1L3* or *IL1B* signal, suggesting there are potentially different mechanisms at play, and that E-COPD may have a stronger mast cell/basophil component. These findings are clinically relevant, as so far there is no specific therapeutic regimen available for either asthma or COPD associated with mixed eosinophilic and neutrophilic airway inflammation.[@CIT0041] This also demonstrates the importance of measuring activation of pathobiological mechanisms, as there could be several underlying factors that result influx of airway inflammatory cells, and therefore treatments targeting particular pathways will be more effective in selected patients where those mechanisms are active.

This study has a number of limitations, including a small sample size that will ultimately need further validation in larger numbers of COPD patients, particularly in relation to the exacerbation prediction. We do not understand the influence of COPD treatments of gene expression levels, and although we could hypothesise that the 6GS is predictive of corticosteroid response as per our asthma data, we need to further test the ability of the biomarker to predict treatment responsiveness. Both *CPA3* and *DNASE1L3* were detected less and had a poorer reproducibility, most likely because of these lower detection rates, however they are still important in E-COPD. Although having a biomarker signature for inflammatory phenotype regardless of the respiratory disease does have advantages, further transcriptomic studies of COPD are warranted and have the potential to identify COPD specific biomarkers for inflammatory phenotype, which may differ from asthma. Further studies are also required to understand stability of COPD inflammatory phenotypes and their relation to 6GS expression levels.

In summary, the present study has shown that the sputum 6-gene expression signature of *CLC, CPA3, DNASE1L3, IL1B, ALPL* and *CXCR2* can serve as a discriminatory biomarker for airway inflammatory phenotypes and exacerbation prone COPD patients. *CLC, CPA3* and *DNASE1L3* were associated with eosinophilic inflammation and *IL1B, ALPL* and *CXCR2* were associated with neutrophilic inflammation. Neutrophilic gene signatures were associated with poor lung function, systemic inflammation, comorbidity, and BODE index. This gene expression signature has the potential to become a useful tool in guiding the management of COPD and accurately identifying phenotypes with different underlying mechanisms and treatment responses.
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[^1]: **Note:** \*GOLD quadrant classified using mMRC data for the symptom score.

    **Abbreviations:** BMI, body mass index; BODE, body mass index, airflow obstruction, dyspnoea and exercise capacity; BDR, bronchodilator responsiveness; CCI, Charlson Comorbidity Index; CRP, C-reactive protein; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; SGRQ, Saint George Respiratory Questionnaire.

[^2]: **Notes:** Data are presented as n (%), mean (SD) or median (quartile 1--3). \*kwalls2 p\<0.001 vs PG-COPD, ^\^^kwallis2 p\<0.001 vs E-COPD, ^\#^kwallis2 p\<0.001 vs N-COPD, ^\~^kwallis2 p\<0.001 vs MG-COPD.

    **Abbreviations:** E-COPD, eosinophilic -- chronic obstructive pulmonary disease; NE-COPD, non-eosinophilic-COPD; N-COPD, neutrophilic-COPD; NN-COPD, non-neutrophilic COPD; BMI, body mass index; FEV~1~, forced expiratory volume in 1 sec; FVC, forced vital capacity; BDR, bronchodilator responsiveness; ICS, inhaled corticosteroid; CCI, Charlson Comorbidity Index; SGRQ, Saint George Respiratory Questionnaire; BODE, body mass index, airflow obstruction, dyspnoea and exercise capacity.

[^3]: **Notes:** Minimal false negatives correspond to the point of the ROC curve with the highest sensitivity (true positive rate, useful for ruling disease out) whereas minimal false positives correspond to the point with the highest specificity (false positive rate, useful for ruling disease in).

    **Abbreviations:** AUC, area under the curve; E-COPD, eosinophilic COPD; MG-COPD, mixed granulocytic COPD; N-COPD, neutrophilic COPD; PG-COPD, paucigranulocytic COPD; E^+ve^-COPD, COPD with sputum eosinophilia (E and MG-COPD); E^−ve^-COPD, COPD without sputum eosinophilia (N and PG-COPD); N^+ve^-COPD, COPD with sputum neutrophilia (N and MG-COPD); N^−ve^-COPD, COPD without sputum neutrophilia (E and PG-COPD).

[^4]: **Abbreviations:** COPD, chronic obstructive pulmonary disease; 6GS, 6 gene expression signature; E-COPD, eosinophilic COPD; N-COPD, neutrophilic COPD; PG-COPD, paucigranulocytic COPD; MG-COPD, mixed granulocytic COPD.

[^5]: **Abbreviations:** COPD, chronic obstructive pulmonary disease; 6GS, 6 gene expression signature; E-COPD, eosinophilic COPD; N-COPD, neutrophilic COPD; PG-COPD, paucigranulocytic COPD; MG-COPD, mixed granulocytic COPD.
